Diabetes Drug Tirzepatide Cuts Alcohol Cravings by Over 50% in New Study

A new study from the University of Gothenburg suggests that tirzepatide, the drug behind the diabetes medication Mounjaro, could help reduce alcohol consumption. Tests on animal models showed a sharp drop in drinking when treated with the compound. Researchers believe the findings may open doors for future treatments targeting alcohol dependence.

In the study, animals given tirzepatide cut their voluntary alcohol intake by over 50%. Even episodes of binge drinking declined significantly. The drug appears to work by altering the brain's reward system, reducing the dopamine response linked to alcohol cravings.

Tirzepatide acts on two key receptors—GIP and GLP-1—which may explain its stronger effect compared to similar medications like semaglutide. Early evidence also suggests it could trigger long-term biological changes in the brain, possibly through epigenetic mechanisms, helping to curb addictive behaviour over time.

Despite these promising results, no clinical trials for tirzepatide as an alcohol dependence treatment have been submitted to regulators like the EMA or FDA as of February 2026. Human studies will be essential before any approval, though the drug's existing use for diabetes might speed up the review process.

The findings highlight tirzepatide's potential as a novel treatment for alcohol dependence, combining immediate effects on cravings with possible lasting brain changes. However, further research in humans is required before it can be considered for regulatory approval. For now, the drug remains untested in clinical settings for this specific use.